All In Biotech

Drug Trial Radar · NCT04893486

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

A Multicenter, Phase 2B, Randomized, Double-Blind, Stratified, Vehicle-Controlled Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel In Prevention Of BCCs In Patients With Gorlin Syndrome

Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

May 6, 2021

Primary completion

Mar 13, 2023

Study completion Mar 13, 2023

Sponsor

Lead sponsor
Palvella Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. This study will be conducted at multiple centers in the United States where participants with Gorlin Syndrome, also known as basal cell nevus syndrome, will be randomly placed into two groups; one group will receive the active topical gel, the other a topical vehicle gel, also know as placebo. Participants will apply this topical product to their face once a day for 6 months. The study will be looking at the number of new BCCs that develop on the faces of all the participants during this time.

Conditions

  • BCCs in Gorlin Syndrome Patients

Interventions

  • PTX-022Drug

    QTORIN 3.9 % Sirolimus Topical Gel

  • Vehicle comparatorDrug

    Vehicle comparator topical gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of new biopsy confirmed BCCs that develop on the face compared between the active and vehicle treatment armsTime frame: Month 6
  2. Incidence of dermatological, treatment emergent adverse events after treatment with activeTime frame: Month 6

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona

  • Burke Pharmaceuticals Research

    Hot Springs, Arkansas

  • Stanford Univeristy

    Palo Alto, California

  • Park Avenue Dermatology

    Orange Park, Florida

  • Ameriderm Research

    Ormond Beach, Florida

  • Gwinett Clinical Research Center

    Snellville, Georgia

  • Clinical Coordinating Center (Minnesota)

    New Brighton, Minnesota

  • Mayo Clinic - Minnesota

    Rochester, Minnesota

  • St. Louis University

    St Louis, Missouri

  • Duke University

    Durham, North Carolina

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania

  • DermResearch Inc

    Austin, Texas

  • University of Utah

    Murray, Utah

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia

  • St. Pancras Clinical Research

    London, United Kingdom

  • Salford Foundation Trust

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.